PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Palynziq

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: ☐ Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	**Specialty/facility name (if applicable):**

☐ REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.

Q1. Is this a reauthorization request? If YES, go to question 2. If NO, go to question 13.

☐ Yes ☐ No

Q2. Is the patient 12 years of age or older?

☐ Yes ☐ No

Q3. Is Palynziq being prescribed by or in consultation with a metabolic diseases specialist or a provider who specializes in the treatment of PKU?

☐ Yes ☐ No

Q4. Does the patient have a diagnosis of uncontrolled phenylketonuria confirmed by baseline blood phenylalanine concentrations greater than 600 micromol/L? Chart notes documenting diagnosis AND baseline labs must be attached.

☐ Yes ☐ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Palynziq

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

Q5. Has the patient tried non-pharmacological treatment options (such as restriction of dietary phenylalanine intake)? Notes must be attached showing the patient has tried and failed dietary restriction in consultation with a nutritionist.

☐ Yes ☐ No

Q6. Does the patient have a documented trial and failure of or contraindication/intolerance to sapropterin dihydrochloride (sapropterin dihydrochloride will require Prior Authorization)? Documentation of contraindication/intolerance or trial and failure (at a dose of 20mg/kg for at least 1 month of therapy) must be attached.

☐ Yes ☐ No

Q7. Has auto-injectable epinephrine been prescribed and has the patient been instructed on proper use and to have it on them at all times? Chart notes documenting that auto-injector epinephrine has been prescribed to the patient and counseling has been done must be attached.

☐ Yes ☐ No

Q8. Is there documentation that the initial dose will be administered under the supervision of a healthcare provider?

☐ Yes ☐ No

Q9. Is there documentation showing Palynziq will be initiated at the recommended induction dose?

☐ Yes ☐ No

Q10. Is there documentation showing Palynziq will be titrated over at least 5 weeks after completing the 4-week induction period to an effective maintenance dosage?

☐ Yes ☐ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Palynziq

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:

Q11. Will the patient be taking a stable maintenance dose of Palynziq concomitantly with sapropterin or sepiapterin (Sephience)? Note: Concomitant use with sapropterin or sepapterin is permitted during Palynziq dose titration.

☐ Yes ☐ No

Q12. FOR RENEWAL: Has the patient been approved for treatment with Palynziq previously?

☐ Yes ☐ No

Q13. FOR RENEWAL: Has the patient experienced any serious side effects (such as anaphylactic events) while being treated with Palynziq?

☐ Yes ☐ No

Q14. FOR RENEWAL: Has the patient been compliant with filling their prescription?

☐ Yes ☐ No

Q15. FOR RENEAL: Is there documentation that the patient is stable on their current dose of Palynziq? Including documentation showing a blood phenylalanine concentration less than or equal to 600 micromol/L? Labs must be attached.

☐ Yes ☐ No

Q16. FOR RENEWAL : Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 24 weeks of continuous treatment with 20 mg subcutaneously once daily? Labs must be attached.

☐ Yes ☐ No

Q17. FOR RENEWAL : Is there a titration plan in place showing that the patient's dosage will be increased to 40 mg subcutaneously once daily for at least 16 weeks?

☐ Yes ☐ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Palynziq

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

Q18. FOR RENEWAL: Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 16 weeks of continuous treatment with 40 mg subcutaneously once daily? Labs must be attached.

☐ Yes ☐ No

Q19. FOR RENEWAL: Is there documentation showing the patient's dosage will be increased to a maximum of 60 mg subcutaneously once daily for at least 16 weeks?

☐ Yes ☐ No

Q20. Additional Information:

______________________________ Prescriber Signature

____________________ Date

v2026

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document